GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT02483299

CompletedPhase 4

Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome

Lead sponsor

University Medical Centre Ljubljana

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, PCOS

Key I/E criterion

•Female

Primary endpoints

•Body weight, absolute change (kg)•Number of good responders to combined treatment regarding body weight

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02483299

Org study IDLIRA COMBI

Timeline

Milestones

Study first posted2015-06-26estimated

Last update posted2015-06-26estimated

Study start2014-01 (month precision)

Primary completion2015-04actual (month precision)

Study completion2015-04actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightPCOS

Eligibility

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•18 years old to menopause

•polycystic ovary syndrome (NICHD criteria)

•BMI of 30 kg/m² or higher

Exclusion criteria

•type 1 or type 2 diabetes mellitus

•history of carcinoma

•Cushing's syndrome or congenital (non-classic) adrenal hyperplasia

•personal or family history of MEN 2

•significant cardiovascular, kidney or hepatic disease

•the use of medications known or suspected to affect reproductive or metabolic functions

•the use of statins, within 90 days prior to study entry

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Weight & body composition

Glycemic / diabetes

Other (unclassified)

Weight & body composition

4 endpoints

Primary/protocol endpoint

Change in body weight

Time frame:up to 12 weeks of clinical trial

Body weight, absolute change (kg)

change from baseline, improvement

Primary/protocol endpoint/low confidence

The number of good responders to combined treatment regarding body weight

Time frame:up to 12 weeks of clinical trial

threshold achievement, improvement

Secondary/protocol endpoint

Change in body mass index (BMI).

Time frame:up to 12 weeks of clinical trial

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change in waist circumference

Time frame:up to 12 weeks of clinical trial

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Other/protocol endpoint

Change in fasting concentrations of glucose

Time frame:up to 12 weeks of clinical trial

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Other/protocol endpoint

Change in fasting concentration of insulin

Time frame:up to 12 weeks of clinical trial

change from baseline, improvement

Other clinical outcomes

5 endpoints

Other/protocol endpoint/low confidence

Change in blood concentrations of LH (luteinizing hormone)

Time frame:up to 12 weeks of clinical trial

change from baseline, improvement

Other/protocol endpoint

Change in blood concentrations of FSH (follicle-stimulating hormone)

Time frame:up to 12 weeks of clinical trial

change from baseline, improvement

Other/protocol endpoint

Change in blood concentration of testosterone

Time frame:up to 12 weeks of clinical trial

Androgen, change

change from baseline, improvement

Other/protocol endpoint

Change in blood concentration in androstenedione

Time frame:up to 12 weeks of clinical trial

Androgen, change

change from baseline, improvement

Other/protocol endpoint

Change in blood concentration of DHEAS (dehydroepiandrosterone sulfate)

Time frame:up to 12 weeks of clinical trial

Androgen, change

change from baseline, improvement

Other (unclassified)

1 endpoint

Other/protocol endpoint/low confidence

Change in blood concentrations of SHBG (sex hormone-binding globulin)

Time frame:up to 12 weeks of clinical trial

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.